<!DOCTYPE html>
<html>
<head>
  <script type="application/ld+json">
    [

      {
        "@context": "https://schema.org/docs/jsonldcontext.jsonld",
        "@type": "Protein",
        "@id": "https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1614#",
        "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/Protein/0.9-DRAFT-2019_08_20/",
        "identifier": "1614",
        "name": "ACE2",
        "associatedDisease": "COVID-19",
        "description": "Receptor on host cells that is exploited by some betacoronaviruses for viral entry. Engaged by SARS-CoV-2 spike protein as the first step towards infection of host cells",
        "url": "https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1614"
      },
      {
        "@context": "https://schema.org/docs/jsonldcontext.jsonld",
        "@type": "Protein",
        "@id": "https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2421#",
        "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/Protein/0.9-DRAFT-2019_08_20/",
        "identifier": "2421",
        "name": "TMPRSS2",
        "associatedDisease": "COVID-19",
        "description": "Involved in the activation of viral glycoproteins/viral entry across a range of viruses, including SARS-CoV-2. SARS-CoV-2 entry is partially blocked in vitro by the protease inhibitor camostat",
        "url": "https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2421"
      },
      {
        "@context": "https://schema.org/docs/jsonldcontext.jsonld",
        "@type": "Protein",
        "@id": "https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3111#",
        "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/Protein/0.9-DRAFT-2019_08_20/",
        "identifier": "3111",
        "name": "SARS-CoV-2 Main protease",
        "associatedDisease": "COVID-19",
        "description": "Inhibitors of this viral protease have the potential to block cleavage of nascent viral proteins as they are synthesised in host cells.",
        "url": "https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3111"
      }

    ]

  </script>
  <script type="application/ld+json">[

    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8912#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "8912",
      "name": "acalabruntinib",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8912",
      "associatedDisease": "COVID-19",
      "description": "acalabrutinib is an approved BTK inhibitor that is used to treat B cell malignancies. It is being progressed to clinical trial in COVID-19 patients as part of the UK's ACCORD initiative https://bit.ly/2ZXjXOw."
    },
    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10478#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "10478",
      "name": "bemcentinib",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10478",
      "associatedDisease": "COVID-19",
      "description": "Bemcentinib is an investigational, selective and orally active AXL receptor tyrosine kinase inhibitor. Part of its mechanism of action is to inhibit proinflammatory cytokine production. It is being progressed to clinical trial in COVID-19 patients as part of the UK's ACCORD initiative https://bit.ly/2ZXjXOw, to determine if its anti-inflammatory action is efficacious in combating COVID-19 associated hyper-inflammatory response."
    },
    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5687#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "5687",
      "name": "imatinib",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5687",
      "associatedDisease": "COVID-19",
      "description": "Abelson kinase (Abl) inhibitors are reported to block Spike protein-induced SARS-CoV and MERS-CoV fusion in vitro PMID:  29557770, potentially by blocking Abl2 at the endosomal membrane PMID: 27466418. It will be informative to determine if this holds true for SARS-CoV-2, and whether re-purposing of imatinib and/or newer Abl kinase inhibitors (dasatinib; bosutinib) could be a viable strategy against COVID-19. Likely to be most effective during the early stage of infection."
    },
    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5678#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "5678",
      "name": "dasatinib",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5678",
      "associatedDisease": "COVID-19",
      "description": "Abelson kinase (Abl) inhibitors are reported to block Spike protein-induced SARS-CoV and MERS-CoV fusion in vitro PMID:  29557770, potentially by blocking Abl2 at the endosomal membrane PMID: 27466418. It will be informative to determine if this holds true for SARS-CoV-2, and whether re-purposing of imatinib and/or newer Abl kinase inhibitors (dasatinib; bosutinib) could be a viable strategy against COVID-19. Likely to be most effective during the early stage of infection."
    },
    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5710#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "5710",
      "name": "bosutinib",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5710",
      "associatedDisease": "COVID-19",
      "description": "Abelson kinase (Abl) inhibitors are reported to block Spike protein-induced SARS-CoV and MERS-CoV fusion in vitro PMID:  29557770, potentially by blocking Abl2 at the endosomal membrane PMID: 27466418. It will be informative to determine if this holds true for SARS-CoV-2, and whether re-purposing of imatinib and/or newer Abl kinase inhibitors (dasatinib; bosutinib) could be a viable strategy against COVID-19. Likely to be most effective during the early stage of infection."
    },
    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6972#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "6972",
      "name": "anakinra",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6972",
      "associatedDisease": "COVID-19",
      "description": "An approved IL-1 pathway blocking peptide, that has anti-inflammatory action. This Comment in The Lancet Rheumatology discusses factors to be considered when planning anakinra trials for COVID-19 hyperinflammatory response https://bit.ly/2yu89Ig"
    },
    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9895#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "9895",
      "name": "apilimod",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9895",
      "associatedDisease": "COVID-19",
      "description": "A clinical stage inhibitor of the type III phosphoinostol kinase, PIKfyve. Anti-SARS-CoV-2 activity in vitro https://www.biorxiv.org/content/10.1101/2020.04.16.044016v1"
    },
    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "name": "aviptadil",
      "associatedDisease": "COVID-19",
      "description": "A VIP analogue, VPAC1 receptor agonist that is already in clinical use. Preclinical and clinical experience shows that aviptadil restores function in pulmonary hypertension, ARDS, and acute lung injury (ALI), reduces IL-6 and TNFalpha production, and protects against pulmonary edema. This combination of benefits has led to aviptadil being investigated as a treatment option for ARDS in COVID-19 patients (NCT04311697)."
    },
    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9412#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "9412",
      "name": "AZD7986 (INS1007, brensocatib)",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9412",
      "associatedDisease": "COVID-19",
      "description": "AZD7986 inhibits activation of neutrophil elastase via direct inhibition of dipeptidyl peptidase 1, that is being investigated as a treament for neutrophilic lung inflammation. It has been shown to produce on-target effects in healthy trial volunteers (PMID: 29484635). Plans are underway to examine the potential of AZD7986 (now being progressed by Insmed as INS1007) to treat COVID-19-related acute respiratory distress syndrome (ARDS), in the UK STOP-COVID19 clinical trial. The INS1007 arm of the study aims to administer the drug to 150 COVID-19 patients (plus 150 in the placebo arm) across 10 UK hospitals. "
    },
    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7792#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "7792",
      "name": "baricitinib",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7792",
      "associatedDisease": "COVID-19",
      "description": "Approved JAK1/2 inhibitor. AI predicts antiviral activity via inhibition of AAK1 which is an important regulator of clathrin-mediated endocytosis, so has potential to inhibit viral entry into host cells in addition to its potent anti-inflammatory efficacy."
    },
    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6771#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "6771",
      "name": "bevacizumab",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6771",
      "associatedDisease": "COVID-19",
      "description": "Approved anti-VEGFA mAb. Phase 2/3 NCT04275414 aims to determine if suppression of vascular permeability will reduce pulmonary edema in patients with severe/critical COVID-19"
    },
    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "sameAs": "https://pubchem.ncbi.nlm.nih.gov/compound/483477",
      "name": "brincidofovir",
      "associatedDisease": "COVID-19",
      "description": "Small-molecule nucleoside analogue antiviral drug that was developed to treat cytomegalovirus, adenovirus, smallpox, and ebolavirus infections. Potential against SARS-CoV-2 infection could be evaluated"
    },
    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6432#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "6432",
      "name": "camostat",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6432",
      "associatedDisease": "COVID-19",
      "description": "Serine protease inhibitor with activity against the host TMPRSS2 protease that is exploited by SARS-CoV-2 to mediate viral entry."
    },

    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9758#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "9758",
      "name": "camrelizumab",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9758",
      "associatedDisease": "COVID-19",
      "description": "An anti-PD-1 checkpoint inhibitor approved in China as an immuno-oncology biologic. Being compared to thymosin for the prevention of sepsis in COVID-19 patients."
    },
    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7469#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "7469",
      "name": "ciclesonide",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7469",
      "associatedDisease": "COVID-19",
      "description": "Ciclesonide (an approved corticosteroid used to treat respiratory inflammation) can inhibit SARS-CoV-2 replication via inhibition of viral nsp15 (bioRxiv preprint article Matsuyama et al. (2020) https://doi.org/10.1101/2020.03.11.987016)."
    },
    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10706#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "10706",
      "name": "compound 11r",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10706",
      "associatedDisease": "COVID-19",
      "description": "This is a compound that inhibits the SARS-CoV main protease (Mpro), and has potential to inhibit the SARS-CoV-2 Mpro, structural similarities between the 2 enzymes permitting. X-ray structure of 11r bound to SARS-CoV Mpro is deposited with the RSCB Protein Databank (ID 5N5O)."
    },
    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10720#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "10720",
      "name": "compound 13b",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10720",
      "associatedDisease": "COVID-19",
      "description": "A more drug-like derivative of 11r (10706) that inhibits the SARS-CoV-2 main protease (Mpro) PMID: 32198291. Exhibits potential for direct delivery to the lungs via inhalation route."
    },

    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7535#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "7535",
      "name": "cobicistat",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7535",
      "associatedDisease": "COVID-19",
      "description": "Antiretroviral, protease inhibitor. Cobicistat increases its bioavailability and half life. Phase 3 NCT04252274 for COVID-19."
    },
    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10737#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "10737",
      "name": "EIDD-2801",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10737",
      "associatedDisease": "COVID-19",
      "description": "A novel, orally bioavailable RNA-dependent RNA polymerase inhibitor, that targets replication of RNA viruses PMID: 32253226. Being advanced to clinical trials in the UK and US."
    },
    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6884#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "6884",
      "name": "eculizumab",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6884",
      "associatedDisease": "COVID-19",
      "description": "Approved mAb that binds complement factor C5 and blocks membrane attack complex formation."
    },
    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9295#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "9295",
      "name": "emapalumab",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9295",
      "associatedDisease": "COVID-19",
      "description": "An approved anti-IFNγ mAb, which could target elevated cytokine production during COVID-19 infection."
    },

    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6811#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "6811",
      "name": "enoxaparin",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6811",
      "associatedDisease": "COVID-19",
      "description": "An approved anti-clotting agent. Given evidence of heparin as a potential attachment factor for the coronavirus, a trial to determine the efficacy of early treatment with enoxaparin in COVID-19 patients has been initiated in Italy (March 2020)."
    },

    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2407#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "2407",
      "name": "fingolimod",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2407",
      "associatedDisease": "COVID-19",
      "description": "An approved S1P1 receptor inhibitor that has immunomodulatory/immunosuppresant actions. This could be applied to the management of the inflammatory aspects of COVID-19. Clinical efficacy will be evaluated in Phase 2 study NCT04280588."
    },

    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9624#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "9624",
      "name": "gimsilumab",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9624",
      "associatedDisease": "COVID-19",
      "description": "An anti-GM-CSF (CSF2) mAb currently in clinical trial for anti-inflammatory potential in the treatment of autoimmune inflammation and cancer. Has been repurposed for deranged inflammation in COVID-19 (Phase 2, NCT04351243)."
    },
    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4214#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "4214",
      "name": "heparin",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4214",
      "associatedDisease": "COVID-19",
      "description": "Heparin is being used in ICU settings (based on observational efficacy) to mitigate against COVID-19-associated thromboembolic events (heart attack, stroke, pulmonary embolism). It is being progressed to clinical trial in COVID-19 patients as part of the UK's ACCORD initiative https://bit.ly/2ZXjXOw."
    },

    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7198#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "7198",
      "name": "hydroxychloroquine",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7198",
      "associatedDisease": "COVID-19",
      "description": "An existing antimalarial drug, with in vitro activity against SARS-CoV (PMID: 16640347), that is being repositioned to treat COVID-19. Preliminary evidence from a small cohort of COVID-19 patients suggests that a combination of hydroxychloroquine + the antibiotic azithromycin significantly reduces detectable viral RNA (compared to hydroxychloroquine alone or placebo; In press 17 March 2020 IJAA DOI : 10.1016/j.ijantimicag.2020.105949). However, extreme caution must be taken when considering using hydroxychloroquine as it has severe cardiac adverse effects, and in addition its distribution to lung tissue is unknown. Read Derek Lowe's 'In the PIPELINE' blog https://blogs.sciencemag.org/pipeline/archives/2020/04/16/more-small-molecule-clinical-data-against-covid-19-as-of-april-16 which provides a systematic and considered anaylsis of the (lack of) potential for hydroxychloroquine/chloroquine for COVID-19."
    },
    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",

      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",

      "name": "leronlimab",

      "associatedDisease": "COVID-19",
      "description": "A clinical stage anti-CCR5 mAb with immunomodulatory potential. Being evaluated in Ph2 clinical trials in COVID-19 patients as a strategy to reduce cytokine storm and related pathophysiological sequelae."
    },
    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",

      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",

      "name": "MDL-28170",

      "associatedDisease": "COVID-19",
      "description": "Anti-SARS-CoV-2 activity in vitro https://www.biorxiv.org/content/10.1101/2020.04.16.044016v1"
    },
    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10692#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "10692",
      "name": "mucolytic drugs",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10692",
      "associatedDisease": "COVID-19",
      "description": "Ambroxol is an approved mucolytic which has the potential to combat pulmonary congestion in numerous lung conditions."
    },
    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4626#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "4626",
      "name": "nafamostat",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4626",
      "associatedDisease": "COVID-19",
      "description": "A protease inhibitor approved in Japan. Now being evaluated in combination with favipiravir in a RCT in patients with COVID-19 pneumonia (clinical trial number jRCTs031200026). Nafamostat is being proposed to reduce SARS-CoV-2 entry by inhibiting the host protease TMPRSS2 [PMID:27550352], and to additionally counteract COVID-19-associated thrombosis via its established anticoagulant activity."
    },
    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10732#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "10732",
      "name": "otamixaban",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10732",
      "associatedDisease": "COVID-19",
      "description": "A direct serine protease factor Xa inhibitor, and failed anticoagulant candidate drug; predicted binding energy when virtually docked  with TRMPSS2; associated with bleeding-related adverse effects in clinical study."
    },
    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10716#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "10716",
      "name": "PRD_002214",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10716",
      "associatedDisease": "COVID-19",
      "description": "PRD_002214 is a viral main protease inhibitor. It has been crystalised in complex with the SARS-CoV-2 Mpro (RCSB Protein Databank ID 6LU7)."
    },

    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7862#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "7862",
      "name": "relacatib",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7862",
      "associatedDisease": "COVID-19",
      "description": "Developed as a cathepsin K inhibitor but has activity against cathepsin L that may provide potential to block SARS-Cov-2 entry into host cells."
    },
    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10715#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "10715",
      "name": "remdesivir",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10715",
      "associatedDisease": "COVID-19",
      "description": "Nucleotide analogue antiviral with broad-spectrum activity against RNA viruses. Used on compassionate grounds to treat the first SARS-CoV-2 +ve patient in the US. Phase 3 trial NCT04292899 to be carried out in patients with severe COVID-19 is in preparation. In combination with chloroquine, effectively inhibits a clinical isolate of SARS-CoV-2 in vitro PMID: 32020029. Derek Lowe provides a systematic and considered anaylsis of the potential for remdesivir in COVID-19 via his 'In the PIPELINE' blog https://blogs.sciencemag.org/pipeline/archives/2020/04/16/more-small-molecule-clinical-data-against-covid-19-as-of-april-16"
    },
    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5535#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "5535",
      "name": "chloroquine",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5535",
      "associatedDisease": "COVID-19",
      "description": "In combination with remdesivir, effectively inhibits a clinical isolate of SARS-CoV-2 in vitro PMID: 32020029."
    },
    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6842#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "6842",
      "name": "ribavirin",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6842",
      "associatedDisease": "COVID-19",
      "description": "Anti-HIV combination (with ritonavir) that could be repurposed for COVID-19."
    },
    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8804#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "8804",
      "name": "ritonavir",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8804",
      "associatedDisease": "COVID-19",
      "description": "Anti-HIV combination (with ribavirin) that could be repurposed for COVID-19. NCT04295551. Update: No significant benefit from ritonavir + lopinavir treatment (compared to standard therapy) was observed in patients with severe COVID-19 (results reported for Chinese trial ChiCTR2000029308 http://www.chictr.org.cn/showprojen.aspx?proj=48684 in NEJM 18/03/2020 PMID: 32187464)"
    },
    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5688#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "5688",
      "name": "ruxolitinib",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5688",
      "associatedDisease": "COVID-19",
      "description": "An approved anti-inflammatory JAK1/2/TYK2 inhibitor. Under clinical evaluation for Covid-19 (in combination with mesenchymal stem cell infusion)."
    },
    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6031#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "6031",
      "name": "sirolimus",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6031",
      "associatedDisease": "COVID-19",
      "description": "An approved immunosuppressive drug. Sirolimus inhibits MERS-CoV infection of human liver cells in vitro; may be applicable to SARS-CoV-2 infection."
    },
    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7327#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "7327",
      "name": "thalidomide",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7327",
      "associatedDisease": "COVID-19",
      "description": "Thalidomide + low-dose glucocorticoid, and thalidomide + celecoxib are two approaches being evaluated for clinical efficacy in patients with severe COVID-19. These combine the immunosuppressive action of thalidomide with the anti-inflammatory actions of glucocorticoids and COX inhibition respectively. See NCT04273529 and NCT04273581 as examples."
    },
    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6881#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "6881",
      "name": "tocilizumab",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6881",
      "associatedDisease": "COVID-19",
      "description": "Approved immunosuppressive anti-IL-6 receptor mAb. China's National Health Commission has authorised its use to treat patients with serious COVID-19-induced lung damage, and results have been posted on the preprint server of the Chinese Academy of Sciences. (ChinaXiv), http://www.chinaxiv.org/abs/202003.00026, DOI: 10.12074/202003.00026. Phase 2 trial TOCIVID-19 (NCT04317092) is underway in Italy."
    },
    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10732#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "10732",
      "name": "I-432",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10732",
      "associatedDisease": "COVID-19",
      "description": "An in vitro tool compound; inhibitor of serine protease TMPRSS2."
    },
    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7999#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "7999",
      "name": "sarilumab",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7999",
      "associatedDisease": "COVID-19",
      "description": "Approved immunosuppressive anti-IL-6 receptor mAb. Four COVID-19 trials underway as of March 30 2020, including the French open-label CORIMUNO-SARI study NCT04324073."
    },
    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10036#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "10036",
      "name": "selinexor",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10036",
      "associatedDisease": "COVID-19",
      "description": "An approved drug that acts as a selective inhibitor of nuclear export (SINE). SINE compounds have been shown to disrupt the replication of multiple viruses in vitro and in vivo and to mediate anti-inflammatory and anti-viral effects in animal models. In respect of SARS-CoV-2, SINE compounds have been reported to exhibit potential to interfere with interactions between viral proteins and key host proteins [PMID:32353859]. Based on this in vitro observation, low-dose selinexor has been advanced to Phase 2 investigation in patients with severe COVID-19 (NCT04349098)."
    },
    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10735#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "10735",
      "name": "β-D-N4-hydroxycytidine",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10735",
      "associatedDisease": "COVID-19",
      "description": "Prelimianry evidence form a BioRxiv preprint indicate that NHC/EIDD-2801 exhibits broad spectrum antiviral activity against SARS-CoV-2, MERS-CoV, SARS-CoV, and related zoonotic group 2b or 2c Bat-CoVs. The potency of NHC/EIDD-2801 against multiple coronaviruses, its therapeutic efficacy, and oral bioavailability in vivo, all highlight its potential utility as an effective antiviral against SARS-CoV-2 and other future zoonotic coronaviruses."
    },
    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10745#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "10745",
      "name": "MDL-28170",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10745",
      "associatedDisease": "COVID-19",
      "description": "Anti-SARS-CoV-2 activity in vitro https://www.biorxiv.org/content/10.1101/2020.04.16.044016v1"
    },
    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10746#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "10746",
      "name": "YBY-825",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10746",
      "associatedDisease": "COVID-19",
      "description": "Anti-SARS-CoV-2 activity in vitro https://www.biorxiv.org/content/10.1101/2020.04.16.044016v1"
    },
    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1077#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "10747",
      "name": "ONO-5334",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10747",
      "associatedDisease": "COVID-19",
      "description": "Anti-SARS-CoV-2 activity in vitro https://www.biorxiv.org/content/10.1101/2020.04.16.044016v1"
    },
    {
      "@context": "https://schema.org/docs/jsonldcontext.jsonld",
      "@type": "MolecularEntity",
      "@id": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10404#",
      "http://purl.org/dc/terms/conformsTo": "https://bioschemas.org/profiles/MolecularEntity/0.4-DRAFT-2019_11_11/",
      "identifier": "10404",
      "name": "zilucoplan",
      "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10404",
      "associatedDisease": "COVID-19",
      "description": "Zilucoplan is an investigational complement pathway inhibitor with anti-inflammatory potential. It acts as a functional inhibitor of membrane attack complex (MAC) formation. It is being progressed to clinical trial in COVID-19 patients as part of the UK's ACCORD initiative https://bit.ly/2ZXjXOw, to determine if it has efficacy in reducing the hyper-inflammatory response that is a component of severe COVID-19."
    }



  ]

  </script>

  </script>
</head>
<body>
<h1>Test Extracted from Guide to Pharmacology</h1>
<p>The scraper should extract markup for 49 MolecularEntity and 3 Protein.</p>
</body>
</html>
